pharma · Dravet Syndrome · Dravet syndrome · STOK
Stoke Therapeutics
Stoke Therapeutics is a pharma organization headquartered in Bedford, USA. It trades on NYSE under ticker STOK. Primary therapeutic focus areas include Dravet Syndrome, Dravet syndrome, Autosomal Dominant Optic Atrophy,
Bedford, USA HQ
2017 Founded
205 Employees
Public company Type
STOK · NYSE Ticker
Company details
- Status
- Public
- HQ
- Bedford, USA
- Founded
- 2017
- Employees
- 205
- Programs
- 8
- Drugs
- 4
- Patents
- 14
STK-002
Phase 1 · small molecule · Autosomal Dominant Optic Atrophy
STK-002 for Autosomal Dominant Optic Atrophy is a Phase 1 program (small_molecule) at Stoke Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code STK-002-OA-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Stoke Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Autosomal Dominant Optic Atrophy
- Status
- active
- Trials
- 1